Revenue Breakdown
Composition ()
No data
Revenue Streams
ADMA Biologics Inc (ADMA) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is ADMA BioManufacturing, accounting for 100.0% of total sales, equivalent to $134.19M. Another important revenue stream is Reconciliation. Understanding this composition is critical for investors evaluating how ADMA navigates market cycles within the Pharmaceuticals industry.
Profitability & Margins
Evaluating the bottom line, ADMA Biologics Inc maintains a gross margin of 63.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 45.09%, while the net margin is 35.48%. These profitability ratios, combined with a Return on Equity (ROE) of 35.56%, provide a clear picture of how effectively ADMA converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ADMA competes directly with industry leaders such as TLX and DNLI. With a market capitalization of $3.95B, it holds a leading position in the sector. When comparing efficiency, ADMA's gross margin of 63.78% stands against TLX's N/A and DNLI's N/A. Such benchmarking helps identify whether ADMA Biologics Inc is trading at a premium or discount relative to its financial performance.
